{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T01:56:05Z","timestamp":1784339765399,"version":"3.55.0"},"reference-count":83,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2023,1,6]],"date-time":"2023-01-06T00:00:00Z","timestamp":1672963200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Merck Sharp &amp; Dohme LLC"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccines"],"abstract":"<jats:p>This study evaluated the clinical and economic impact of routine pediatric vaccination with the 15-valent pneumococcal conjugate vaccine (PCV15, V114) compared with the 13-valent PCV (PCV13) from a societal perspective in the United States (US). A Markov decision-analytic model was constructed to estimate the outcomes for the entire US population over a 100-year time horizon. The model estimated the impact of V114 versus PCV13 on pneumococcal disease (PD) incidence, post meningitis sequalae, and deaths, taking herd immunity effects into account. V114 effectiveness was extrapolated from the observed PCV13 data and PCV7 clinical trials. Costs (2021$) included vaccine acquisition and administration costs, direct medical costs for PD treatment, direct non-medical costs, and indirect costs, and were discounted at 3% per year. In the base case, V114 prevented 185,711 additional invasive pneumococcal disease, 987,727 all-cause pneumonia, and 11.2 million pneumococcal acute otitis media cases, compared with PCV13. This led to expected gains of 90,026 life years and 96,056 quality-adjusted life years with a total saving of $10.8 billion. Sensitivity analysis showed consistent results over plausible values of key model inputs and assumptions. The findings suggest that V114 is a cost-saving option compared to PCV13 in the routine pediatric vaccination program.<\/jats:p>","DOI":"10.3390\/vaccines11010135","type":"journal-article","created":{"date-parts":[[2023,1,9]],"date-time":"2023-01-09T02:09:39Z","timestamp":1673230179000},"page":"135","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Cost-Effectiveness Analysis of Routine Use of 15-Valent Pneumococcal Conjugate Vaccine in the US Pediatric Population"],"prefix":"10.3390","volume":"11","author":[{"given":"Min","family":"Huang","sequence":"first","affiliation":[{"name":"Merck & Co., Inc., Rahway, NJ 07065, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianyan","family":"Hu","sequence":"additional","affiliation":[{"name":"Merck & Co., Inc., Rahway, NJ 07065, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Weaver","sequence":"additional","affiliation":[{"name":"Merck & Co., Inc., Rahway, NJ 07065, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4519-2857","authenticated-orcid":false,"given":"Kwame","family":"Owusu-Edusei","sequence":"additional","affiliation":[{"name":"Merck & Co., Inc., Rahway, NJ 07065, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9993-8036","authenticated-orcid":false,"given":"Elamin","family":"Elbasha","sequence":"additional","affiliation":[{"name":"Merck & Co., Inc., Rahway, NJ 07065, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,1,6]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/S1473-3099(04)00938-7","article-title":"Streptococcus pneumoniae colonisation: The key to pneumococcal disease","volume":"4","author":"Bogaert","year":"2004","journal-title":"Lancet Infect. Dis."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"338","DOI":"10.12688\/f1000research.22341.1","article-title":"Recent advances in the epidemiology and prevention of Streptococcus pneumoniae infections","volume":"9","author":"Feldman","year":"2020","journal-title":"F1000Research"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/S0891-5520(05)70270-1","article-title":"The prevention of pneumococcal disease by vaccines: Promises and challenges","volume":"15","author":"Poland","year":"2001","journal-title":"Infect. Dis. Clin. N. Am."},{"key":"ref_4","unstructured":"Advisory Committee on Immunization Practices (2000). Preventing pneumococcal disease among infants and young children. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep., 49, 1\u201335."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1128\/CMR.00018-12","article-title":"Pediatric invasive pneumococcal disease in the United States in the era of pneumococcal conjugate vaccines","volume":"25","author":"Tan","year":"2012","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1007\/s12325-013-0007-6","article-title":"The impact of 7-valent pneumococcal conjugate vaccine on invasive pneumococcal disease: A literature review","volume":"30","author":"Myint","year":"2013","journal-title":"Adv. Ther."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/j.idc.2015.07.009","article-title":"Pneumococcal Disease in the Era of Pneumococcal Conjugate Vaccine","volume":"29","author":"Yildirim","year":"2015","journal-title":"Infect. Dis. Clin. N. Am."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Schiess, N., Groce, N.E., and Dua, T. (2021). The Impact and Burden of Neurological Sequelae Following Bacterial Meningitis: A Narrative Review. Microorganisms, 9.","DOI":"10.3390\/microorganisms9050900"},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Weycker, D., Farkouh, R.A., Strutton, D.R., Edelsberg, J., Shea, K.M., and Pelton, S.I. (2016). Rates and costs of invasive pneumococcal disease and pneumonia in persons with underlying medical conditions. BMC Health Serv. Res., 16.","DOI":"10.1186\/s12913-016-1432-4"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"3398","DOI":"10.1016\/j.vaccine.2011.02.088","article-title":"Healthcare utilization and cost of pneumococcal disease in the United States","volume":"29","author":"Huang","year":"2011","journal-title":"Vaccine"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"7479","DOI":"10.1016\/j.vaccine.2018.10.060","article-title":"Acute otitis media, antimicrobial prescriptions, and medical expenses among children in the United States during 2011\u20132016","volume":"36","author":"Suaya","year":"2018","journal-title":"Vaccine"},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Tong, S., Amand, C., Kieffer, A., and Kyaw, M.H. (2018). Trends in healthcare utilization and costs associated with pneumonia in the United States during 2008-2014. BMC Health Serv. Res., 18.","DOI":"10.1186\/s12913-018-3529-4"},{"key":"ref_13","unstructured":"Centers for Disease Control and Prevention (2022, September 06). Pneumococcal Disease Surveillance and Reporting, Available online: https:\/\/www.cdc.gov\/pneumococcal\/surveillance.html."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"S740","DOI":"10.1093\/ofid\/ofaa439.1660","article-title":"1479. Incidence of Acute Otitis Media in Children in the United States before and after the introduction of Pneumococcal Conjugate Vaccines (PCV7 and PCV13) during 1998-2018","volume":"7","author":"Hu","year":"2020","journal-title":"Open Forum Infect. Dis."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"S741","DOI":"10.1093\/ofid\/ofaa439.1661","article-title":"1480. Incidence of Non-Invasive Pneumococcal Pneumonia in Children in the United States before and after Introduction Pneumococcal Conjugate Vaccines (PCV7 and PCV13) during 1998-2018","volume":"7","author":"Hu","year":"2020","journal-title":"Open Forum Infect. Dis."},{"key":"ref_16","first-page":"1","article-title":"Prevention of pneumococcal disease among infants and children\u2014Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine\u2014Recommendations of the Advisory Committee on Immunization Practices (ACIP)","volume":"59","author":"Nuorti","year":"2010","journal-title":"MMWR Recomm. Rep."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.3201\/eid2706.204238","article-title":"Twenty-Year Public Health Impact of 7- and 13-Valent Pneumococcal Conjugate Vaccines in US Children","volume":"27","author":"Wasserman","year":"2021","journal-title":"Emerg. Infect. Dis."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.vaccine.2013.05.005","article-title":"Impact of pneumococcal conjugate vaccines on nasopharyngeal carriage and invasive disease among unvaccinated people: Review of evidence on indirect effects","volume":"32","author":"Davis","year":"2013","journal-title":"Vaccine"},{"key":"ref_19","unstructured":"Poehling, K.K.M. (2022, March 15). Introduction of the Pneumococcal Working Group, Available online: www.cdc.gov\/vaccines\/acip\/meetings\/downloads\/slides-2020-10\/pneumo-01-Poehling-Kobayashi-508.pdf."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Linley, E., Bell, A., Gritzfeld, J.F., and Borrow, R. (2019). Should Pneumococcal Serotype 3 Be Included in Serotype-Specific Immunoassays?. Vaccines, 7.","DOI":"10.3390\/vaccines7010004"},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Balsells, E., Guillot, L., Nair, H., and Kyaw, M.H. (2017). Serotype distribution of Streptococcus pneumoniae causing invasive disease in children in the post-PCV era: A systematic review and meta-analysis. PLoS ONE, 12.","DOI":"10.1371\/journal.pone.0177113"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/S2352-4642(18)30168-8","article-title":"Effectiveness of 13-valent pneumococcal conjugate vaccination for protection against acute otitis media caused by Streptococcus pneumoniae in healthy young children: A prospective observational study","volume":"2","author":"Pichichero","year":"2018","journal-title":"Lancet Child. Adolesc. Health"},{"key":"ref_23","unstructured":"Pilishvili, T. (2022, May 31). 13-Valent Pneumococcal Conjugate Vaccine (PCV13) Effects on Disease Caused by Serotype 3, Available online: https:\/\/www.cdc.gov\/vaccines\/acip\/meetings\/downloads\/min-archive\/min-2019-02-508.pdf."},{"key":"ref_24","unstructured":"Food and Drug Administration (2022, September 06). Label for Pneumococcal 15-Valent Conjugate Vaccine, Available online: https:\/\/nctr-crs.fda.gov\/fdalabel\/services\/spl\/set-ids\/1158fa93-ef41-4a29-8252-9251f94c53c8\/spl-doc?hl=Pneumococcal%2015-valent%20Conjugate%20Vaccine."},{"key":"ref_25","unstructured":"Merck & Co., Inc. (2022, October 24). European Commission Expands Merck\u2019s VAXNEUVANCE\u2122 (Pneumococcal 15-Valent Conjugate Vaccine) Indication to Include Infants, Children and Adolescents. Available online: https:\/\/www.merck.com\/news\/european-commission-expands-mercks-vaxneuvance-pneumococcal-15-valent-conjugate-vaccine-indication-to-include-infants-children-and-adolescents\/."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"e511","DOI":"10.1016\/j.cmi.2019.09.008","article-title":"Multistate population and whole genome sequence-based strain surveillance of invasive pneumococci recovered in the USA during 2017","volume":"26","author":"Varghese","year":"2020","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_27","unstructured":"Merck & Co., Inc. (2022, October 24). U.S. FDA Approves Merck\u2019s VAXNEUVANCE\u2122 (Pneumococcal 15-Valent Conjugate Vaccine) for the Prevention of Invasive Pneumococcal Disease in Infants and Children. Available online: https:\/\/www.merck.com\/news\/u-s-fda-approves-mercks-vaxneuvance-pneumococcal-15-valent-conjugate-vaccine-for-the-prevention-of-invasive-pneumococcal-disease-in-infants-and-children\/."},{"key":"ref_28","unstructured":"Lupinacci, R.R.R., Wittawatmongkol, O., Jones, J., Qui\u00f1ones, J., Ulukol, B., Dagan, R., Richmond, P., Stek, J., Romero, L., and Koseoglu, S. (2022, January 19\u201323). A phase 3, multicenter, randomized, double-blind, active-comparator-controlled study to evaluate concomitant administration of pediatric vaccines with a 4-dose regimen of V114 in healthy infants (PNEU-PED). Proceedings of the 12th Biennial International Symposium on Pneumococci & Pneumococcal Diseases (ISPPD), Toronto, ON, Canada."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.15585\/mmwr.mm7137a3","article-title":"Use of 15-Valent Pneumococcal Conjugate Vaccine Among U.S. Children: Updated Recommendations of the Advisory Committee on Immunization Practices\u2014United States, 2022","volume":"71","author":"Kobayashi","year":"2022","journal-title":"MMWR Morb. Mortal. Wkly. Rep."},{"key":"ref_30","unstructured":"Smith, D., Gravelle, H., and The Practice of Discounting Economic Evaluation of Health Care Interventions (2022, March 15). The University of York. Available online: https:\/\/www.york.ac.uk\/che\/pdf\/tp19.pdf."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/S1473-3099(10)70048-7","article-title":"Global and regional risk of disabling sequelae from bacterial meningitis: A systematic review and meta-analysis","volume":"10","author":"Edmond","year":"2010","journal-title":"Lancet Infect. Dis."},{"key":"ref_32","unstructured":"The United States Census Bureau (2022, March 15). National Population by Characteristics 2010\u20132019, Available online: https:\/\/www.census.gov\/data\/tables\/time-series\/demo\/popest\/2010s-national-detail.html#par_textimage_98372960."},{"key":"ref_33","unstructured":"Arias, E., and Xu, J.Q. (2022, March 15). United States Life Tables, Available online: https:\/\/www.cdc.gov\/nchs\/data\/nvsr\/nvsr69\/nvsr69-12-508.pdf."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.15585\/mmwr.mm6740a4","article-title":"Vaccination Coverage Among Children Aged 19\u201335 Months\u2014United States, 2017","volume":"67","author":"Hill","year":"2018","journal-title":"MMWR Morb. Mortal. Wkly. Rep."},{"key":"ref_35","unstructured":"Centers for Disease Control and Prevention (2022, March 15). Bacterial Core Surveillance Report, Emerging Infections Program Network. Centers for Disease Control and Prevention, Available online: http:\/\/www.cdc.gov\/abcs\/reports-findings\/survreports\/spneu18.pdf."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.jinf.2010.04.008","article-title":"The risk of sequelae due to pneumococcal meningitis in high-income countries: A systematic review and meta-analysis","volume":"61","author":"Jit","year":"2010","journal-title":"J. Infect."},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Hu, T., Song, Y., Done, N., Liu, Q., Sarpong, E.M., Lemus-Wirtz, E., Signorovitch, J., Mohanty, S., and Weiss, T. (2022). Incidence of invasive pneumococcal disease in children with commercial insurance or Medicaid coverage in the United States before and after the introduction of 7- and 13-valent pneumococcal conjugate vaccines during 1998\u20132018. BMC Public Health, 22.","DOI":"10.1186\/s12889-022-14051-6"},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Hu, T., Done, N., Petigara, T., Mohanty, S., Song, Y., Liu, Q., Lemus-Wirtz, E., Signorovitch, J., Sarpong, E., and Weiss, T. (2022). Incidence of acute otitis media in children in the United States before and after the introduction of 7- and 13-valent pneumococcal conjugate vaccines during 1998\u20132018. BMC Infect. Dis., 22.","DOI":"10.1186\/s12879-022-07275-9"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s10096-021-04324-0","article-title":"Dynamic changes in otopathogens colonizing the nasopharynx and causing acute otitis media in children after 13-valent (PCV13) pneumococcal conjugate vaccination during 2015-2019","volume":"41","author":"Kaur","year":"2022","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"ref_40","unstructured":"Centers for Disease Control and Prevention (2022, November 06). Centers for Disease Control ABC Surveillance. In Centers for Disease Control and Prevention, ed. Data on File. 2010\u20132019, Available online: https:\/\/www.cdc.gov\/."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1093\/cid\/civ368","article-title":"Impact of the 13-Valent Pneumococcal Conjugate Vaccine on Pneumococcal Meningitis in US Children","volume":"61","author":"Olarte","year":"2015","journal-title":"Clin. Infect. Dis."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/S1473-3099(14)71081-3","article-title":"Effect of use of 13-valent pneumococcal conjugate vaccine in children on invasive pneumococcal disease in children and adults in the USA: Analysis of multisite, population-based surveillance","volume":"15","author":"Moore","year":"2015","journal-title":"Lancet Infect. Dis."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.3201\/eid2209.150680","article-title":"Trends in Pneumonia Mortality Rates and Hospitalizations by Organism, United States, 2002\u20132011(1)","volume":"22","author":"Wuerth","year":"2016","journal-title":"Emerg. Infect. Dis."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1016\/S0140-6736(06)69637-2","article-title":"Effectiveness of seven-valent pneumococcal conjugate vaccine against invasive pneumococcal disease: A matched case-control study","volume":"368","author":"Whitney","year":"2006","journal-title":"Lancet"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/S2213-2600(16)00052-7","article-title":"Effectiveness of 13-valent pneumococcal conjugate vaccine for prevention of invasive pneumococcal disease in children in the USA: A matched case-control study","volume":"4","author":"Moore","year":"2016","journal-title":"Lancet Respir Med."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJM200102083440602","article-title":"Efficacy of a pneumococcal conjugate vaccine against acute otitis media","volume":"344","author":"Eskola","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1097\/00006454-200003000-00003","article-title":"Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children","volume":"19","author":"Black","year":"2000","journal-title":"Pediatr Infect. Dis. J."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"e20170181","DOI":"10.1542\/peds.2017-0181","article-title":"Epidemiology of Acute Otitis Media in the Postpneumococcal Conjugate Vaccine Era","volume":"140","author":"Kaur","year":"2017","journal-title":"Pediatrics"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1086\/323027","article-title":"Pneumococcal conjugate vaccine serotypes of Streptococcus pneumoniae isolates and the antimicrobial susceptibility of such isolates in children with otitis media","volume":"33","author":"Joloba","year":"2001","journal-title":"Clin. Infect. Dis."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"4947","DOI":"10.1016\/j.vaccine.2008.07.016","article-title":"Impact of the introduction of pneumococcal conjugate vaccine on rates of community acquired pneumonia in children and adults","volume":"26","author":"Nelson","year":"2008","journal-title":"Vaccine"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1007\/s40273-019-00805-5","article-title":"Cost Effectiveness of Elderly Pneumococcal Vaccination in Presence of Higher-Valent Pneumococcal Conjugate Childhood Vaccination: Systematic Literature Review with Focus on Methods and Assumptions","volume":"37","author":"Treskova","year":"2019","journal-title":"Pharmacoeconomics"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"2043","DOI":"10.1001\/jama.294.16.2043","article-title":"Changing epidemiology of invasive pneumococcal disease among older adults in the era of pediatric pneumococcal conjugate vaccine","volume":"294","author":"Lexau","year":"2005","journal-title":"JAMA"},{"key":"ref_53","unstructured":"Centers for Disease Control and Prevention (2005). Direct and indirect effects of routine vaccination of children with 7-valent pneumococcal conjugate vaccine on incidence of invasive pneumococcal disease--United States, 1998\u20132003. MMWR Morb Mortal Wkly. Rep., 54, 893\u2013897."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"e324","DOI":"10.1542\/peds.2012-3350","article-title":"Cost-effectiveness of using 2 vs. 3 primary doses of 13-valent pneumococcal conjugate vaccine","volume":"132","author":"Stoecker","year":"2013","journal-title":"Pediatrics"},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"Szende, A., Janssen, B., and Cabases, J. (2014). Self-Reported Population Health: An International Perspective Based on EQ-5D, Springer Nature.","DOI":"10.1007\/978-94-007-7596-1"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"7634","DOI":"10.1016\/j.vaccine.2010.09.049","article-title":"Public health and economic impact of the 13-valent pneumococcal conjugate vaccine (PCV13) in the United States","volume":"28","author":"Rubin","year":"2010","journal-title":"Vaccine"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1183\/13993003.00325-2015","article-title":"Cost-effectiveness of adult pneumococcal conjugate vaccination in the Netherlands","volume":"46","author":"Mangen","year":"2015","journal-title":"Eur. Respir. J."},{"key":"ref_58","unstructured":"Bureau of Labor Statistics (2022, March 15). CPI for All Urban Consumers (CPI-U): Medical Care in U.S. City Average, All Urban Consumers, Not Seasonally Adjusted, Available online: https:\/\/www.bls.gov\/news.release\/archives\/cpi_01122022.pdf."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1097\/01.inf.0000222403.42974.8b","article-title":"Cost-effectiveness of pneumococcal conjugate vaccine: Evidence from the first 5 years of use in the United States incorporating herd effects","volume":"25","author":"Ray","year":"2006","journal-title":"Pediatr. Infect. Dis. J."},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"Hu, T. (BMC Health Serv. Res., 2022). Economic Burden of Pneumococcal Disease in Children in the United States after the Introduction of 13-Valent Pneumococcal Conjugate Vaccines during 2014\u20132018, BMC Health Serv. Res., under review.","DOI":"10.1186\/s12913-023-09244-7"},{"key":"ref_61","unstructured":"Stoecker, C. (2022, March 15). Economic Assessment of PCV15 & PCV20, Available online: https:\/\/stacks.cdc.gov\/view\/cdc\/109109."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1007\/s10935-015-0394-3","article-title":"Estimated Human and Economic Burden of Four Major Adult Vaccine-Preventable Diseases in the United States, 2013","volume":"36","author":"McLaughlin","year":"2015","journal-title":"J. Prim. Prev."},{"key":"ref_63","unstructured":"Centers for Disease Control and Prevention (2004). Economic costs associated with mental retardation, cerebral palsy, hearing loss, and vision impairment\u2014United States, 2003. MMWR Morb. Mortal. Wkly. Rep., 53, 57\u201359."},{"key":"ref_64","unstructured":"Bureau of Labor Statistics (2022, March 15). Median Usual Weekly Earnings of Full-Time Wage and Salary Workers by Age, Race, Hispanic or Latino Ethnicity, and Sex, Fourth Quarter 2021 Averages, Not Seasonally Adjusted. Bureau of Labor Statistics, Available online: https:\/\/www.bls.gov\/news.release\/wkyeng.t03.htm."},{"key":"ref_65","unstructured":"Bureau of Labor Statistics (2022, March 15). Civilian Labor Force Participation Rate by Age, Sex, Race, and Ethnicity. Bureau of Labor Statistics, Available online: https:\/\/www.bls.gov\/emp\/tables\/civilian-labor-force-participation-rate.htm."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1080\/14760584.2022.2112179","article-title":"Predicting effectiveness of the V114 vaccine against invasive pneumococcal disease in children","volume":"21","author":"Ryman","year":"2022","journal-title":"Expert Rev. Vaccines"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"e234","DOI":"10.1093\/pubmed\/fdab159","article-title":"A review of health-related quality of life associated with pneumococcal disease: Pooled estimates by age and type of disease","volume":"44","author":"Tang","year":"2022","journal-title":"J. Public Health"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1056\/NEJMoa022823","article-title":"Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine","volume":"348","author":"Whitney","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1016\/S0140-6736(07)60564-9","article-title":"Decline in pneumonia admissions after routine childhood immunisation with pneumococcal conjugate vaccine in the USA: A time-series analysis","volume":"369","author":"Grijalva","year":"2007","journal-title":"Lancet"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1542\/peds.2007-0619","article-title":"Trends in acute otitis media-related health care utilization by privately insured young children in the United States, 1997\u20132004","volume":"121","author":"Zhou","year":"2008","journal-title":"Pediatrics"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1016\/j.vaccine.2004.08.051","article-title":"Pneumococcal pneumonia in the UK\u2014How herd immunity affects the cost-effectiveness of 7-valent pneumococcal conjugate vaccine (PCV)","volume":"23","author":"McIntosh","year":"2005","journal-title":"Vaccine"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1001\/jama.283.11.1460","article-title":"Projected cost-effectiveness of pneumococcal conjugate vaccination of healthy infants and young children","volume":"283","author":"Lieu","year":"2000","journal-title":"Jama"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"6483","DOI":"10.1016\/j.vaccine.2009.08.045","article-title":"Cost-effectiveness of pneumococcal conjugate vaccine: An update after 7 years of use in the United States","volume":"27","author":"Ray","year":"2009","journal-title":"Vaccine"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"4267","DOI":"10.1016\/j.vaccine.2012.04.028","article-title":"Cost-effectiveness of 13-valent pneumococcal conjugate vaccine in Switzerland","volume":"30","author":"Blank","year":"2012","journal-title":"Vaccine"},{"key":"ref_75","doi-asserted-by":"crossref","unstructured":"Earnshaw, S.R., McDade, C.L., Zanotti, G., Farkouh, R.A., and Strutton, D. (2012). Cost-effectiveness of 2 + 1 dosing of 13-valent and 10-valent pneumococcal conjugate vaccines in Canada. BMC Infect. Dis., 12.","DOI":"10.1186\/1471-2334-12-101"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.clinthera.2012.12.006","article-title":"Cost-effectiveness of a 10- versus 13-valent pneumococcal conjugate vaccine in Denmark and Sweden","volume":"35","author":"Klok","year":"2013","journal-title":"Clin. Ther."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.jinf.2011.10.015","article-title":"Cost-effectiveness of 13-valent pneumococcal conjugate vaccine: Germany, Greece, and The Netherlands","volume":"64","author":"Strutton","year":"2012","journal-title":"J. Infect."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1016\/j.vaccine.2018.01.052","article-title":"The role of timeliness in the cost-effectiveness of older adult vaccination: A case study of pneumococcal conjugate vaccine in Australia","volume":"36","author":"Chen","year":"2018","journal-title":"Vaccine"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1007\/s11606-016-3651-0","article-title":"Incremental Cost-Effectiveness of 13-valent Pneumococcal Conjugate Vaccine for Adults Age 50 Years and Older in the United States","volume":"31","author":"Stoecker","year":"2016","journal-title":"J. Gen. Intern. Med."},{"key":"ref_80","unstructured":"Gierke, R. (2022, March 15). Current Epidemiology of Pneumococcal Disease, United States\u20142019 Updates. Centers for Disease Control and Prevention, Advisory Committee on Immunication Practices, Available online: https:\/\/www.cdc.gov\/vaccines\/acip\/meetings\/downloads\/slides-2021-06\/02-Pneumococcal-Gierke-508.pdf."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/S1473-3099(19)30297-X","article-title":"Pneumococcal lineages associated with serotype replacement and antibiotic resistance in childhood invasive pneumococcal disease in the post-PCV13 era: An international whole-genome sequencing study","volume":"19","author":"Lo","year":"2019","journal-title":"Lancet Infect. Dis."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1093\/infdis\/jiac154","article-title":"Impact of Pneumococcal Conjugate Vaccines on Antibiotic-Nonsusceptible Invasive Pneumococcal Disease in the United States","volume":"226","author":"Bajema","year":"2022","journal-title":"J. Infect. Dis."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/2047-2994-3-16","article-title":"Attributable healthcare utilization and cost of pneumonia due to drug-resistant streptococcus pneumonia: A cost analysis","volume":"3","author":"Reynolds","year":"2014","journal-title":"Antimicrob. Resist. Infect. Control"}],"container-title":["Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-393X\/11\/1\/135\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T18:01:43Z","timestamp":1760119303000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-393X\/11\/1\/135"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,6]]},"references-count":83,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,1]]}},"alternative-id":["vaccines11010135"],"URL":"https:\/\/doi.org\/10.3390\/vaccines11010135","relation":{},"ISSN":["2076-393X"],"issn-type":[{"value":"2076-393X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,6]]}}}